For in vitro diagnostic use. Others Elecsys CA 125 II IVD Elecsys® CA 125 II CPS_000447 07 026 986 188 7 026 986 188 07026986188 7026986188 07026986188 CA 125 G2 Elecsys E2G 300 Elecsys CA 125 II 07613336194157 Reagents, kits 300 tests cobas e 402/801 09 755 586 190 9 755 586 190 09755586190 9755586190 09755586190 CA 125 G2 Elecsys E2G 100 V1 CA 125 G2 Elecsys E2G 100 V1 07613336218327 Reagents, kits 100 tests cobas e 402/801 true 11 776 223 161 11776223161 CA 125 G2 Elecsys cobas e 100 Elecsys CA 125 II 04015630945795 Reagents, kits 100 tests cobas e 411/601/602 true 11 776 223 214 11776223214 CA 125 G2 Elecsys cobas e 100 Elecsys CA 125 II 07613336162880 Reagents, kits 100 tests cobas e 411/601/602 true 07 026 986 190 7 026 986 190 07026986190 7026986190 07026986190 CA 125 G2 Elecsys E2G 300 Elecsys CA 125 II 04015630939633 Reagents, kits 300 tests cobas e 402/801 true 07 026 986 214 7 026 986 214 07026986214 7026986214 07026986214 CA 125 G2 Elecsys E2G 300 Elecsys CA 125 II 07613336194140 Reagents, kits 300 tests cobas e 402/801 true 11 776 223 190 11776223190 CA 125 G2 Elecsys cobas e 100 Elecsys CA 125 II 04015630939497 Reagents, kits 100 tests cobas e 411/601/602 true 09755586501 Elecsys CA 125 II en 1 FF0000000701620E FF0000000701610E 09755586190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum, Li‑heparin, K2‑EDTA and K3‑EDTA, as well as Li‑heparin plasma tubes containing separating gel on cobas e analyzers.These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential).This immunoassay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma. This immunoassay is further indicated for use in monitoring patients for disease progress or response to therapy.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 09755586500 Elecsys CA 125 II en 1 FF000000066E160E FF000000066E150E 09755586190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum and plasma.These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential).This assay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first‑line therapy and would be considered for second-look procedures. This assay is further indicated for serial measurement of CA 125 to aid in the management of cancer patients.This assay is also intended to be used in conjunction with the Elecsys HE4 assay as part of ROMA (Risk Of Ovarian Malignancy Algorithm) for the risk assessment of ovarian cancer in pre- and postmenopausal women presenting with pelvic mass.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 11776223501 Elecsys CA 125 II en 3 FF0000000714970E FF0000000145D10E 11776223161 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum, Li‑heparin, K2‑EDTA and K3‑EDTA, as well as Li‑heparin plasma tubes containing separating gel on the cobas e analyzers.These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential).This immunoassay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma. This immunoassay is further indicated for use in monitoring patients for disease progress or response to therapy.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 11776223500 Elecsys CA 125 II en 5 FF0000000515320E FF00000000DBBE0E 11776223190 11776223214 618 cobas e 411 2325 cobas e 602 619 cobas e 601 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum and plasma.These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential).This assay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first‑line therapy and would be considered for second-look procedures. This assay is further indicated for serial measurement of CA 125 to aid in the management of cancer patients.This assay is also intended to be used in conjunction with the Elecsys HE4 assay as part of ROMA (Risk Of Ovarian Malignancy Algorithm) for the risk assessment of ovarian cancer in premenopausal and postmenopausal women presenting with pelvic mass.The electrochemiluminescence immunoassay “ECLIA” is intended for use on Elecsys and cobas e immunoassay analyzers. en 07026986501 Elecsys CA 125 II en 1 FF00000001EBD10E FF00000001EBD10E 07026986190 2497 cobas e 801 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum, Li‑heparin, K2‑EDTA and K3‑EDTA, as well as Li‑heparin plasma tubes containing separating gel on cobas e analyzers.These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential).This immunoassay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma. This immunoassay is further indicated for use in monitoring patients for disease progress or response to therapy.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07026986500 Elecsys CA 125 II en 8 FF0000000549C40E FF0000000521580E 07026986190 07026986214 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum and plasma.These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential).This assay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma in patients who have undergone first‑line therapy and would be considered for second-look procedures. This assay is further indicated for serial measurement of CA 125 to aid in the management of cancer patients.This assay is also intended to be used in conjunction with the Elecsys HE4 assay as part of ROMA (Risk Of Ovarian Malignancy Algorithm) for the risk assessment of ovarian cancer in pre- and postmenopausal women presenting with pelvic mass.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en 07026986501 Elecsys CA 125 II en 2 FF0000000588ED0E FF0000000588ED0E 07026986190 2497 cobas e 801 9494 cobas e 402 Product information shown on this page contains elements of the officially released Method Sheet. If you require further information please refer to the full Method Sheet PDF under the given link, or contact your local Roche country representative. Intended useImmunoassay for the in vitro quantitative determination of OC 125 reactive determinants in human serum, Li‑heparin, K2‑EDTA and K3‑EDTA, as well as Li‑heparin plasma tubes containing separating gel on cobas e analyzers.These determinants are associated with a high molecular weight glycoprotein in serum and plasma of women with primary epithelial invasive ovarian cancer (excluding those with cancer of low malignant potential).This immunoassay is indicated for use as an aid in the detection of residual or recurrent ovarian carcinoma. This immunoassay is further indicated for use in monitoring patients for disease progress or response to therapy.The electrochemiluminescence immunoassay “ECLIA” is intended for use on cobas e immunoassay analyzers. en

User Profile

Select your user profile

Elecsys^® CA 125 II

Overview

Detailed Specifications

Ordering Information

Compatible Instruments

Technical Documents

Access important product documentation including relevant certificates and other resources.